These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
565 related articles for article (PubMed ID: 15381643)
1. Prognostic impact of plasma N-terminal pro-brain natriuretic peptide in severe chronic congestive heart failure: a substudy of the Carvedilol Prospective Randomized Cumulative Survival (COPERNICUS) trial. Hartmann F; Packer M; Coats AJ; Fowler MB; Krum H; Mohacsi P; Rouleau JL; Tendera M; Castaigne A; Anker SD; Amann-Zalan I; Hoersch S; Katus HA Circulation; 2004 Sep; 110(13):1780-6. PubMed ID: 15381643 [TBL] [Abstract][Full Text] [Related]
2. NT-proBNP in severe chronic heart failure: rationale, design and preliminary results of the COPERNICUS NT-proBNP substudy. Hartmann F; Packer M; Coats AJ; Fowler MB; Krum H; Mohacsi P; Rouleau JL; Tendera M; Castaigne A; Trawinski J; Amann-Zalan I; Hoersch S; Katus HA Eur J Heart Fail; 2004 Mar; 6(3):343-50. PubMed ID: 14987586 [TBL] [Abstract][Full Text] [Related]
3. The relationship between N-terminal pro-brain natriuretic peptide and risk for hospitalization and mortality is curvilinear in patients with chronic heart failure. Schou M; Gustafsson F; Corell P; Kistorp CN; Kjaer A; Hildebrandt PR Am Heart J; 2007 Jul; 154(1):123-9. PubMed ID: 17584564 [TBL] [Abstract][Full Text] [Related]
5. Prognostic importance of plasma NT-pro BNP in chronic heart failure in patients treated with a beta-blocker: results from the Carvedilol Or Metoprolol European Trial (COMET) trial. Olsson LG; Swedberg K; Cleland JG; Spark PA; Komajda M; Metra M; Torp-Pedersen C; Remme WJ; Scherhag A; Poole-Wilson P; Eur J Heart Fail; 2007 Aug; 9(8):795-801. PubMed ID: 17693380 [TBL] [Abstract][Full Text] [Related]
6. [Comparative prognostic value of plasma and urinary N-terminal pro-B-type natriuretic peptide in patients with acute destabilized heart failure]. Manzano-Fernández S; Januzzi JL; Boronat García M; Bonaque-González JC; Muñoz-Esparza C; Albaladejo-Otón MD; Pastor-Pérez FJ; Pastor P; Valdés M; Pascual-Figal DA Rev Esp Cardiol; 2011 May; 64(5):365-72. PubMed ID: 21397374 [TBL] [Abstract][Full Text] [Related]
7. Effect of beta-blockade and ACE inhibition on B-type natriuretic peptides in stable patients with systolic heart failure. Rosenberg J; Gustafsson F; Remme WJ; Riegger GA; Hildebrandt PR Cardiovasc Drugs Ther; 2008 Aug; 22(4):305-11. PubMed ID: 18309461 [TBL] [Abstract][Full Text] [Related]
8. Plasma amino-terminal pro-brain natriuretic peptide: a novel approach to the diagnosis of cardiac dysfunction. Campbell DJ; Mitchelhill KI; Schlicht SM; Booth RJ J Card Fail; 2000 Jun; 6(2):130-9. PubMed ID: 10908087 [TBL] [Abstract][Full Text] [Related]
9. Usefulness of N-terminal pro-brain natriuretic Peptide and brain natriuretic peptide to predict cardiovascular outcomes in patients with heart failure and preserved left ventricular ejection fraction. Grewal J; McKelvie RS; Persson H; Tait P; Carlsson J; Swedberg K; Ostergren J; Lonn E Am J Cardiol; 2008 Sep; 102(6):733-7. PubMed ID: 18773998 [TBL] [Abstract][Full Text] [Related]
10. Combined use of high-sensitivity cardiac troponin T and N-terminal pro-B type natriuretic peptide improves measurements of performance over established mortality risk factors in chronic heart failure. de Antonio M; Lupon J; Galan A; Vila J; Urrutia A; Bayes-Genis A Am Heart J; 2012 May; 163(5):821-8. PubMed ID: 22607860 [TBL] [Abstract][Full Text] [Related]
11. Long-term results of intensified, N-terminal-pro-B-type natriuretic peptide-guided versus symptom-guided treatment in elderly patients with heart failure: five-year follow-up from TIME-CHF. Sanders-van Wijk S; Maeder MT; Nietlispach F; Rickli H; Estlinbaum W; Erne P; Rickenbacher P; Peter M; Pfisterer MP; Brunner-La Rocca HP; Circ Heart Fail; 2014 Jan; 7(1):131-9. PubMed ID: 24352403 [TBL] [Abstract][Full Text] [Related]
12. Aminoterminal pro type B natriuretic peptide as a predictive and prognostic marker in patients with chronic heart failure. Rothenburger M; Wichter T; Schmid C; Stypmann J; Tjan TD; Berendes E; Etz C; Pioux A; Löher A; Wenzelburger F; Drees G; Hoffmeier A; Breithardt G; Scheld HH J Heart Lung Transplant; 2004 Oct; 23(10):1189-97. PubMed ID: 15477114 [TBL] [Abstract][Full Text] [Related]
13. The effect of beta-blocker (carvedilol) therapy on N-terminal pro-brain natriuretic peptide levels and echocardiographic findings in patients with congestive heart failure. Gundogdu F; Bozkurt E; Kiziltunc A; Sevimli S; Arslan S; Gurlertop Y; Senocak H; Karakelleoglu S Echocardiography; 2007 Feb; 24(2):113-7. PubMed ID: 17313541 [TBL] [Abstract][Full Text] [Related]
14. Comparison of midregional pro-atrial natriuretic peptide with N-terminal pro-B-type natriuretic peptide in predicting survival in patients with chronic heart failure. von Haehling S; Jankowska EA; Morgenthaler NG; Vassanelli C; Zanolla L; Rozentryt P; Filippatos GS; Doehner W; Koehler F; Papassotiriou J; Kremastinos DT; Banasiak W; Struck J; Ponikowski P; Bergmann A; Anker SD J Am Coll Cardiol; 2007 Nov; 50(20):1973-80. PubMed ID: 17996563 [TBL] [Abstract][Full Text] [Related]
15. Hyponatremia, natriuretic peptides, and outcomes in acutely decompensated heart failure: results from the International Collaborative of NT-proBNP Study. Mohammed AA; van Kimmenade RR; Richards M; Bayes-Genis A; Pinto Y; Moore SA; Januzzi JL Circ Heart Fail; 2010 May; 3(3):354-61. PubMed ID: 20332419 [TBL] [Abstract][Full Text] [Related]
16. The prognostic use of right heart catheterization data in patients with advanced heart failure: how relevant are invasive procedures in the risk stratification of advanced heart failure in the era of neurohormones? Gardner RS; Henderson G; McDonagh TA J Heart Lung Transplant; 2005 Mar; 24(3):303-9. PubMed ID: 15737757 [TBL] [Abstract][Full Text] [Related]
17. N-terminal pro-B-type natriuretic peptide and long-term mortality in stable coronary heart disease. Kragelund C; Grønning B; Køber L; Hildebrandt P; Steffensen R N Engl J Med; 2005 Feb; 352(7):666-75. PubMed ID: 15716560 [TBL] [Abstract][Full Text] [Related]
18. N-terminal pro brain natriuretic peptide-guided management in patients with heart failure and preserved ejection fraction: findings from the Trial of Intensified versus standard medical therapy in elderly patients with congestive heart failure (TIME-CHF). Maeder MT; Rickenbacher P; Rickli H; Abbühl H; Gutmann M; Erne P; Vuilliomenet A; Peter M; Pfisterer M; Brunner-La Rocca HP; Eur J Heart Fail; 2013 Oct; 15(10):1148-56. PubMed ID: 23657728 [TBL] [Abstract][Full Text] [Related]
19. Acute changes in N-terminal pro-B-type natriuretic peptide during hospitalization and risk of readmission and mortality in patients with heart failure. Michtalik HJ; Yeh HC; Campbell CY; Haq N; Park H; Clarke W; Brotman DJ Am J Cardiol; 2011 Apr; 107(8):1191-5. PubMed ID: 21296322 [TBL] [Abstract][Full Text] [Related]
20. N-terminal pro-brain natriuretic peptide on admission has prognostic value across the whole spectrum of acute coronary syndromes. Galvani M; Ottani F; Oltrona L; Ardissino D; Gensini GF; Maggioni AP; Mannucci PM; Mininni N; Prando MD; Tubaro M; Vernocchi A; Vecchio C; Circulation; 2004 Jul; 110(2):128-34. PubMed ID: 15197143 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]